Valuation: BLS Pharmaceuticals Limited

Market Cap 24Cr 17Cr 15Cr 14Cr 13Cr 24Cr 1.64TCr 170.37Cr 66Cr 836.48Cr 64Cr 63Cr 2.72TCr P/E 2025
17.8x
P/E 2026 13.9x
Enterprise Value 24Cr 17Cr 15Cr 14Cr 13Cr 24Cr 1.61TCr 166.98Cr 65Cr 819.84Cr 63Cr 62Cr 2.67TCr EV / Sales 2025
2.82x
EV / Sales 2026 2.82x
Free-Float
41.59%
Yield 2025 *
-
Yield 2026 -
1 day-8.23%
1 week-10.17%
1 month+12.17%
3 months+6.00%
6 months+112.00%
Current year+152.38%
1 week 1.03
Extreme 1.03
1.3
1 month 0.9
Extreme 0.9
1.3
Current year 0.36
Extreme 0.36
1.3
1 year 0.33
Extreme 0.33
1.3
3 years 0.04
Extreme 0.04
1.3
5 years 0.04
Extreme 0.04
1.3
10 years 0.04
Extreme 0.04
1.4
Manager TitleAgeSince
Chief Executive Officer - 19/05/2023
Director of Finance/CFO 72 01/09/2016
Chief Operating Officer - -
Director TitleAgeSince
Chairman 67 05/12/2012
Director/Board Member 72 30/06/2022
Director/Board Member - 19/05/2023
Date Insider Type Main position Quantity % Market Cap. Importance
14/05/26 Buy 50,00,000 0.2202%
14/05/26 Exercice 50,00,000 0.2202%
22/03/26 Buy

Chief Executive Officer

18,00,000 0.0804%
Change 5-day change 1-year change 3-year change Capi.($)
-8.23%-10.17%+178.95%+606.67% 19Cr
+1.46%+4.59%+8.65%+31.91% 4.76TCr
+3.24%+1.79%+51.32%+35.51% 4.41TCr
-1.51%+1.93%+9.23%+89.24% 4.15TCr
+3.75%+1.02%+356.94%+574.41% 4.09TCr
-0.62%+0.11%+1.12%+46.02% 2.97TCr
+0.61%+0.90%+24.81%+153.66% 1.72TCr
+2.05%+1.09%+25.56%+41.98% 1.51TCr
+2.26%-4.10% - - 1.47TCr
+5.93%-0.37%+1.05% - 1.38TCr
Average +0.87%+0.41%+73.07%+197.42% 2.65TCr
Weighted average by Cap. +1.63%+0.96%+74.17%+148.31%

Financials

2025 2026
Net sales 2.93Cr 2.05Cr 1.81Cr 1.7Cr 1.55Cr 2.91Cr 197.13Cr 20Cr 7.92Cr 100.33Cr 7.71Cr 7.54Cr 326.48Cr 7.39Cr 5.18Cr 4.56Cr 4.3Cr 3.92Cr 7.33Cr 497.6Cr 52Cr 20Cr 253.25Cr 19Cr 19Cr 824.11Cr
Net income 49.01L 34.37L 30.24L 28.5L 26.01L 48.63L 33Cr 3.42Cr 1.33Cr 17Cr 1.29Cr 1.26Cr 55Cr 1.54Cr 1.08Cr 94.99L 89.54L 81.69L 1.53Cr 103.66Cr 11Cr 4.16Cr 53Cr 4.05Cr 3.97Cr 171.68Cr
Net Debt -61.34L -43.02L -37.84L -35.67L -32.55L -60.87L -41Cr -4.28Cr -1.66Cr -21Cr -1.62Cr -1.58Cr -68Cr -48.56L -34.06L -29.96L -28.24L -25.76L -48.18L -33Cr -3.39Cr -1.31Cr -17Cr -1.28Cr -1.25Cr -54Cr
Logo BLS Pharmaceuticals Limited
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries: Japan, Australia, the United Kingdom, and Czechia. The Company directs the sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.
Employees
-
Date Price Change Volume
24/26/24 A$1.060 -8.23% 16,19,547
23/26/23 A$1.155 -2.12% 3,58,665
22/26/22 A$1.180 -2.07% 4,01,103
21/26/21 A$1.205 -6.59% 2,70,570
18/26/18 A$1.290 +9.32% 15,42,718

Annual profits - Rate of surprise